KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Cash & Equivalents (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Cash & Equivalents data on record, last reported at $41.0 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 36.28% year-over-year to $41.0 million; the TTM value through Sep 2025 reached $41.0 million, up 36.28%, while the annual FY2024 figure was $44.3 million, 25.44% up from the prior year.
  • Cash & Equivalents reached $41.0 million in Q3 2025 per NKTR's latest filing, down from $43.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $152.3 million in Q2 2021 and bottomed at $25.2 million in Q4 2021.
  • Average Cash & Equivalents over 5 years is $64.4 million, with a median of $50.7 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: plummeted 87.32% in 2021, then skyrocketed 249.86% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $25.2 million in 2021, then surged by 249.86% to $88.2 million in 2022, then plummeted by 60.02% to $35.3 million in 2023, then increased by 25.44% to $44.3 million in 2024, then dropped by 7.28% to $41.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $41.0 million in Q3 2025, $43.0 million in Q2 2025, and $38.9 million in Q1 2025.